企业流程再造联合血栓通用于急性缺血性卒中静脉溶栓临床观察  

Clinical Observation on Business Process Reengineering Combined with Xueshuantong Injection for Intravenous Thrombolysis in Patients with Acute Ischemic Stroke

作　　者：何柳[1] 王蕾[1] 方升[1] 姜帅[1] 徐广会 李妮[1] 龚蕉椒[1] 罗业涛 张仲[1] HE Liu;WANG Lei;FANG Sheng;JIANG Shuai;XU Guanghui;LI Ni;GONG Jiaojiao;LUO Yetao;ZHANG Zhong(The Third People' s Hospital of Chengdu,Chengdu,Sichuan,China 610031;School of Public Health and Management,Chongqing MedicalUniversity,Chongqing,China 400016)

机构地区：[1]四川省成都市第三人民医院,四川成都610031 [2]重庆医科大学公共卫生与管理学院,重庆400016

出　　处：《中国药业》2019年第14期63-66,共4页China Pharmaceuticals

基　　金：四川省成都市科技局科技惠民技术研发项目[2015-HM01-00240-SF]

摘　　要：目的探讨企业流程再造(BPR)联合血栓通对急性缺血性卒中(AIS)患者静脉溶栓的疗效。方法选取医院神经内科2012年7月至2017年12月收治的发病后3.5h内入院的AIS患者(431例),以2012年7月至2014年7月的患者为对照组(187例),以2014年8月至2017年12月的患者为观察组(244例)。两组中接受静脉溶栓的患者均给予注射用血栓通静脉滴注。结果观察组静脉溶栓率为62.30%,显著高于对照组的13.37%(P<0.05);观察组入院至静脉溶栓时间(DNT)为62min,显著短于对照组的82min;观察组DNT<60min的比例为53.29%,显著高于对照组的28.00%(P<0.05);两组患者预后相关指标及不良反应发生率无显著差异(P>0.05)。结论BPR理论联合注射用血栓通用于AIS患者静脉溶栓,可显著提高溶栓率,缩短DNT,且不增加不良反应。Objective To investigate the effect of business process reengineering(BPR)combined with Xueshuantong Injection on intravenous thrombolysis in patients with acute ischemic stroke(AIS).Methods Totally 431 AIS patients within 3.5 h after onset admitted to the Department of Neurology in our hospital from July 2012 to December 2017 were selected and divided into the control group(187 cases,from July 2012 to July 2014)and the observation group(244 cases,from August 2014 to December 2017).The patients receiving intravenous thrombolysis in both groups were given intravenous drip of Xueshuantong Injection.Results The intravenous thrombolysis rate in the observation group was 62.30%,which was significantly higher than 13.37%in the control group(P<0.05).The door to needle time(DNT)in the observation group was 62 min,which was significantly shorter than 82 min in the control group,the proportion of DNT<60 min in the observation group was 53.29%,which was significantly higher than 28.00%in the control group(P<0.05).There was no significant difference in prognostic indicators and the incidence of adverse reactions between the two groups(P>0.05).Conclusion BPR theory combined with Xueshuantong Injection for intravenous thrombolysis in patients with AIS can significantly improve thrombolysis rate,shorten DNT without increasing the adverse reactions.

关 键 词：企业流程再造 血栓通 急性缺血性卒中 静脉溶栓 入院至静脉溶栓时间 

分 类 号：R969.4[医药卫生—药理学] R2-031[医药卫生—药学]